The STAMPEDE trial and celecoxib: how to adapt?
Publication
, Journal Article
Armstrong, AJ
Published in: Lancet Oncol
May 2012
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
May 2012
Volume
13
Issue
5
Start / End Page
443 / 445
Location
England
Related Subject Headings
- Sulfonamides
- Pyrazoles
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Male
- Humans
- Celecoxib
- Antineoplastic Agents
- Androgen Antagonists
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J. (2012). The STAMPEDE trial and celecoxib: how to adapt? Lancet Oncol, 13(5), 443–445. https://doi.org/10.1016/S1470-2045(12)70111-0
Armstrong, Andrew J. “The STAMPEDE trial and celecoxib: how to adapt?” Lancet Oncol 13, no. 5 (May 2012): 443–45. https://doi.org/10.1016/S1470-2045(12)70111-0.
Armstrong AJ. The STAMPEDE trial and celecoxib: how to adapt? Lancet Oncol. 2012 May;13(5):443–5.
Armstrong, Andrew J. “The STAMPEDE trial and celecoxib: how to adapt?” Lancet Oncol, vol. 13, no. 5, May 2012, pp. 443–45. Pubmed, doi:10.1016/S1470-2045(12)70111-0.
Armstrong AJ. The STAMPEDE trial and celecoxib: how to adapt? Lancet Oncol. 2012 May;13(5):443–445.
Published In
Lancet Oncol
DOI
EISSN
1474-5488
Publication Date
May 2012
Volume
13
Issue
5
Start / End Page
443 / 445
Location
England
Related Subject Headings
- Sulfonamides
- Pyrazoles
- Prostatic Neoplasms
- Oncology & Carcinogenesis
- Male
- Humans
- Celecoxib
- Antineoplastic Agents
- Androgen Antagonists
- 3211 Oncology and carcinogenesis